Company / Current Liabilities
Ernexa Therapeutics Inc. Current Liabilities History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$3.1M
FY2025
5-year range
$2.4M / $6.6M
FY2021-FY2025
Trend
+6.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $2M in FY2020 to $11M in FY2017.
Based on SEC 10-K filings.
$3M in FY2025 with a 10-year CAGR of -4.9%.
Improved from $7M to $3M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +5.7%
- 10-Year CAGR
- -4.9%
Key checks
Key Insights
- 5-year CAGR of +5.7%, indicating consistent growth.
- In FY2025, current liabilities increased 6.0% year-over-year.
- Peak current liabilities was recorded in FY2017.
- Lowest current liabilities in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.1M | +6.0% |
| FY2024 | $2.9M | -55.3% |
| FY2023 | $6.6M | +178.5% |
| FY2020 | $2.4M | -61.3% |
| FY2019 | $6.1M | +51.5% |
| FY2018 | $4.0M | -62.6% |
| FY2017 | $10.7M | +61.8% |
| FY2016 | $6.6M | +29.7% |
| FY2015 | $5.1M | -27.8% |
| FY2014 | $7.1M | +96.6% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026